美国食品和药物管理局发布200多封药品拒绝信, 提高批准过程的透明度. FDA publishes 200+ rejection letters for drugs, enhancing transparency in approval process.

林业发展局发表了200多封关于药物应用的拒绝信,为决策过程提供了新的透明度,并提出了常见缺陷。 The FDA has published over 200 rejection letters for drug applications, offering new transparency into its decision-making process and common deficiencies cited. 这些完整的回复函可在林业发展局开放的FDA数据库中查阅,现已编辑,以保护商业秘密。 These Complete Response Letters, available on the FDA's openFDA database, are redacted to protect trade secrets. 此举旨在向药品开发商和投资者提供更可预测的服务,并加快新疗法的批准程序。 This move aims to provide drug developers and investors with more predictability and to speed up the approval process for new treatments.